The present invention addresses the problem of providing: a low-dose hyperphosphatemia treatment agent that can substantially reduce serum phosphorus concentration; and particles. The present invention provides a hyperphosphatemia treatment agent that contains, as an active ingredient, particles that include: a crosslinked polymer that has a substituent that includes an NR